OR WAIT null SECS
Reaching for Minimal Symptom Expression in gMG With Inebilizumab, with Richard Nowak, MD, MS
New data from the phase 3 MINT trial (NCT04524273) has continued to support inebilizumab’s effect of reducing exacerbations and rescue therapy use in people with generalized myasthenia gravis (MG), while successfully tapering steroids.1
These findings were presented at the Myasthenia Gravis Foundation of America (MGFA) 2025 meeting in The Hague last month by principal investigator Richard Nowak, MD, MS, associate professor of neurology, and director of Clinical & Translational Neuromuscular Research and the Yale Myasthenia Gravis Clinic at Yale School of Medicine.
The trial included 238 participants, with 2 subsets of patients with generalized MG, AChR+ (n = 95 each randomized to inebilizumab or placebo) and MuSK+ (n = 24 each randomized to inebilizumab or placebo) patients. Overall, through week 26, inebilizumab-treated patients had a hazard ratio of 0.41(95% CI, 0.24-0.70; P = .001) of exacerbations compared to the placebo-treated group. Rescue therapy was used by 8.4% of the inebilizumab-treated patients compared with 23.9% of the placebo-treated patients (P = .005), while all patients were able to achieve a mean steroid dose of around 5 mg a day.
HCPLive spoke with Nowak to learn more about inebilizumab’s potential in addressing current unmet needs for people with generalized MG. He discussed some of the unique advantages inebilizumab offers for this population and went over data highlights from the trial.
“Only about 25% to maybe a third of individuals actually achieve [minimal symptom expression] in the currently available data that we have from trials. So, there certainly continues to be an unmet need from the perspective of adequately treating patients with generalized MG, and that’s where inibilizumab comes in,” Nowak said.
